Pharma companies influence many areas of medicine

Pharma companies influence many areas of medicine

Drug manufacturers have used money to increase their clout with patient advocacy groups, clinical guidelines and physicians, according to a series of commentaries published in JAMA Internal Medicine.  

NPR and ProPublica summarized many of the concerns, saying the papers provide “further evidence showing how conflicts of interest help shape” healthcare.

In one example, researchers found advocacy groups receiving funding from opioid manufacturers were less supportive of federal guidelines designed to limit opioid prescriptions for chronic pain.

“More people are dying than ever before from these products, and it's important to know how the market is shaped by the spending of drug companies," G. Caleb Alexander, co-director of the Center for Drug Safety and Effectiveness at Johns Hopkins University, said to NPR and ProPublica.

For more on the studies, including how many patient advocacy groups are getting cash from the pharmaceutical industry, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.